Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including once-weekly (OW) subcutaneous (s.c.)and once-daily (OD) oral formulations of semaglutide, are a well-established treatment option for type 2 diabetes (T2D), with proven beneficial effects on glycated haemoglobin (HbA1c) and body weight (BW) [1]. Here, GLP1R is linked to type 2 diabetes mellitus.